GlobeNewswire by notified

Beter Bed introduces data-driven sleep advice with Beter Slapen ID

Share

We’re all different and we all have different requirements where sleep is concerned. That makes choosing the right mattress no easy matter. And a lot of people don’t know whether they actually prefer a hard or soft mattress or something in between. Beter Bed aims to help! By screening customers and letting them feel for themselves what a good night’s sleep means, the Beter Slapen ID system takes just a few minutes to provide an independent mattress recommendation based on the customer's personal needs. Introduction of the new system is in line with the company’s strategy presented last year for modernising its current stores.

Beter Bed intends switching to three different types of stores. The first are experience stores such as the one recently opened at the Sontplein retail area in Groningen; these stores have a strategic function within a region. They will be joined by city stores, with the first (200 m2) opening at the Mall of the Netherlands in June. Beter Bed also aims to introduce this concept in inner-city shopping streets. Over the next few years, the company's current shopping-centre stores will also be modernised.

Beter Slapen ID: personal, data-driven sleep advice
In line with its “Sleep Better, Live Better” mission, Beter Bed is supporting these shopping concepts with a new service: Beter Slapen ID. This system uses sensors to measure the customer's body and matches the results with data about our entire mattress range. Using the results of this test combined with the knowledge of our sleep consultants, we can offer customised, independent mattress advice. The device has been successfully tested in two stores over the past few months.

"During tests with this new technology, it became clear that many people have very different preferences than they initially thought. In the near future, Beter Bed wants to make it possible for people to take measurements themselves at home so as to discover their ideal sleep solution. Customers can already be measured in 12 stores in the Netherlands (Groningen Sontplein, Den Bosch, Zoeterwoude, Amsterdam Arena, Rotterdam Alexandrium, Heerlen, Veenendaal, Breda, Leeuwarden, Apeldoorn, and The Hague) and in the Belgian city of Genk. A whole series of measurements and thousands of calculations provide an objective overview of the five most suitable mattresses within just five minutes. And that’s only the beginning, many more will follow", says a proud Perijn Hoefsloot, responsible for Strategic Business Development at Beter Bed.

Following the success of the Peter de Beter Bed-weter campaign, the introduction of the Beter Slapen ID will be supported by an extensive marketing campaign on TV, radio and online.


About Beter Bed Holding
Beter Bed Holding (BBH) is the Netherlands’ leading sleep specialist in retail, wholesale and B2B.

Our mission is simple. We believe that the better we sleep, the happier, healthier and more productivewe are. And we won’t rest until everyone gets the high-quality sleep they deserve.

Listed on Euronext Amsterdam, BBH operates the successful retail brands Beter Bed, Beddenreus, the new subscription brand Leazzzy and the digital organisation LUNEXT. In addition, through its subsidiary DBC International, BBH has a wholesale business in branded products in the bedroom furnishings sector, which includes the well-known international brand M line.

With 4 distribution centres, a fleet of 80 vehicles, 134 stores, a fast-growing online presence, and a wholesale company our team of over 1,000 dedicated employees generated € 214.2 million revenue in 2021.

Providing expert sleep advice is at the very heart of our strategy, and thanks to our revolutionary ‘Beter Slapen ID’ tool, our sleep consultants help customers to get the perfect night’s sleep. BBH is proud that
M line is the official sleep supplier of AFC Ajax, TeamNL, Jumbo-Visma, NOC*NSF and the KNVB.


For more information
Press enquiries: Uneke Dekkers / CFF Communications
T +31 (0)20 575 4010 or M +31 (0)6 50261626
E uneke.dekkers@cffcommunications.nl


For the Pdf version of the press release please click on the link below. Press photos can be downloaded here.


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sampo plc’s share buybacks 13/05/202216.5.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 16/05/2022 at 08:30 am Sampo plc’s share buybacks 13/05/2022 On 13/05/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)25,54545.62AQEU38,57245.68CEUX9,72545.63TQEX96,15845.65XHELTOTAL170,00045.65 *rounded to two decimals On 30 March 2022, Sampo announced a share buyback programme of up to a maximum of EUR 250 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 31 March 2022, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 4,679,141 Sampo A shares representing 0.87 per cent of the total number of shares in Sampo plc. Details

Notes of the Board of Directors on Q1 202216.5.2022 07:30:00 CEST | Press release

NOTES OF THE BOARD OF DIRECTORS ON Q1 2022 REGULATED INFORMATION Brussels, 16 May 2022 07.30 am CEST KEY FIGURES For Q1 2022 we note the following key data: Net result of €21.8 million, or €2.18 per shareRental income up by €2.1 millionLoan-to-value on the investment portfolio down by two percentage points at 53.7%Sale of the buildings The Crescent (Anderlecht, Belgium) and Monnet 4 (Kirchberg, Luxembourg) resulting a profit of €5 millionThe average financing cost fell from 2.07% in 2021 to 2.05% on 31 March 2022Developments on Cloche d’Or continue apace, with the sale of the Kockelscheuer building in January 2022 and delivery of the Darwin II buildingAt the Tour&Taxis site the apartments of the first-phase of Park Lane are gradually being delivered, while events can once again take place in the Sheds, Maison de la Poste and Gare Maritime 16-05-2022-EN FINAL Attachment 16-05-2022-EN FINAL

ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference16.5.2022 07:00:00 CEST | Press release

GENEVA, Switzerland May16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 10:30 a.m. EST on Tuesday, May 24, 2022. A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website. About ObsEva ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroi

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease16.5.2022 00:00:00 CEST | Press release

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. “The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the tre

Cool Company Ltd. – Mandatory Notification of Trade15.5.2022 14:52:24 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Primary insider notification form